A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Gilead Sciences
M.D. Anderson Cancer Center
Thomas Jefferson University
Precision Biologics, Inc
Dana-Farber Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Servier
EQRx International, Inc.
1200 Pharma, LLC
OHSU Knight Cancer Institute
SCRI Development Innovations, LLC
University of Texas Southwestern Medical Center
Aravive, Inc.
Rutgers, The State University of New Jersey
Columbia University
Hoosier Cancer Research Network
Seagen Inc.
Barbara Ann Karmanos Cancer Institute
Nektar Therapeutics
US Oncology Research
Washington University School of Medicine
Swiss Cancer Institute
Alliance Foundation Trials, LLC.
Ascentage Pharma Group Inc.
Jazz Pharmaceuticals
Sun Yat-sen University
Washington University School of Medicine
University of Texas Southwestern Medical Center
University of Alabama at Birmingham
Halozyme Therapeutics
Lumos Pharma
Incyte Corporation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Celgene
Celgene
Celgene
Celgene
Osaka Medical College
The Cooper Health System
Cambridge University Hospitals NHS Foundation Trust
Novartis
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pfizer
NYU Langone Health
University of Pittsburgh
Radiation Therapy Oncology Group
Western Regional Medical Center
Western Regional Medical Center